A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells.
Yu ChenCarlos A TristanLu ChenVukasin M JovanovicClaire MalleyPei-Hsuan ChuSeungmi RyuTao DengPinar OrmanogluDingyin TaoYuhong FangJaroslav SlameckaHyenjong HongChristopher A LeClairSam MichaelChristopher P AustinAnton SimeonovIlyas SingeçPublished in: Nature methods (2021)
Human pluripotent stem cells (hPSCs) are capable of extensive self-renewal yet remain highly sensitive to environmental perturbations in vitro, posing challenges to their therapeutic use. There is an urgent need to advance strategies that ensure safe and robust long-term growth and functional differentiation of these cells. Here, we deployed high-throughput screening strategies to identify a small-molecule cocktail that improves viability of hPSCs and their differentiated progeny. The combination of chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) enhanced cell survival of genetically stable hPSCs by simultaneously blocking several stress mechanisms that otherwise compromise cell structure and function. CEPT provided strong improvements for several key applications in stem-cell research, including routine cell passaging, cryopreservation of pluripotent and differentiated cells, embryoid body (EB) and organoid formation, single-cell cloning, and genome editing. Thus, CEPT represents a unique poly-pharmacological strategy for comprehensive cytoprotection, providing a rationale for efficient and safe utilization of hPSCs.
Keyphrases
- induced apoptosis
- single cell
- pluripotent stem cells
- small molecule
- genome editing
- cell cycle arrest
- stem cells
- crispr cas
- endothelial cells
- cell therapy
- endoplasmic reticulum stress
- rna seq
- signaling pathway
- bone marrow
- risk assessment
- oxidative stress
- mass spectrometry
- induced pluripotent stem cells
- mesenchymal stem cells
- climate change
- living cells
- life cycle
- liquid chromatography
- protein protein